Quarterly report pursuant to Section 13 or 15(d)

Other Intangible Assets

v3.10.0.1
Other Intangible Assets
 9 Months Ended
Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Other Intangible Assets

4. OTHER INTANGIBLE ASSETS

 

The net carrying value of the identifiable intangible assets as of September 30, 2018 and December 31, 2017 are as follows:

 

          As of September 30, 2018     As of December 31, 2017  
          (unaudited)        
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
Diagnostic assets:                        
Asuragen acquisition:                        
Thyroid     9     $ 8,519     $ 8,519  
RedPath acquisition:                        
Pancreas test     7       16,141       16,141  
Barrett’s test     9       18,351       18,351  
Total           $ 43,011     $ 43,011  
Diagnostic lab:                        
CLIA Lab     2.3     $ 609     $ 609  
                         
Accumulated Amortization           $ (12,954 )   $ (10,515 )
                         
Net Carrying Value           $ 30,666     $ 33,105  


 

Amortization expense was approximately $0.8 million for the three-month periods ended September 30, 2018 and 2017, respectively, and approximately $2.4 million for the nine-month periods ended September 30, 2018 and 2017, respectively. Amortization of our diagnostic assets begins upon launch of the product. Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:

 

2018     2019     2020     2021     2022  
$ 3,252     $ 3,252     $ 5,292     $ 4,908     $ 2,987